SNCA and Parkinson disease: However, Gonzalez-Riano et al., using a metabolomics approach to find PD biomarkers in a large Spanish population, found that PA levels were reduced in subjects who went on to develop Parkinson’s disease and proposed that alpha synuclein acted as a transporter, promoting uptake of PA into the brain where it could promote damage [53].